Press release
Venous Thromboembolism Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Quercis Pharma, Anthos Therapeutics, Bayer, BMS, Janssen, O
Venous Thromboembolism Pipeline
The dynamics of the Venous Thromboembolism market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, extensive research and development activities of pharmaceutical companies, and the launch of the emerging pipeline therapies in the market.
"Venous Thromboembolism Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Venous Thromboembolism Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Learn More About Key Developments in the Venous Thromboembolism Therapeutics Market:
https://www.delveinsight.com/report-store/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Venous Thromboembolism Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Venous Thromboembolism Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Venous Thromboembolism treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Venous Thromboembolism market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Venous Thromboembolism Therapeutics Analysis
Globally, several major pharma and biotech giants are developing therapies for Venous Thromboembolism. Currently, Quercis Pharma is leading the therapeutics market with its Venous Thromboembolism drug candidates in the most advanced stage of clinical development.
The Key Companies in the Venous Thromboembolism Therapeutics Market Include:
- Quercis Pharma
- Tethere# Pharmaceuticals
- Ono Pharmaceutical
- Anthos Therapeutics
- Bristol Myers Squibb
- Yuhan Corporation
- Supergene
- Tasly Pharmaceutical
- GlycoMimetics
- Bayer Pharmaceuticals
- Janssen Pharmaceuticals
- Verseon Corporation
- Bayer Pharmaceuticals/
- Ionis Pharma
And Many More
Venous Thromboembolism Drugs Covered in the Report Include:
- Isoquercetin: Quercis Pharma
- Abelacimab: Anthos therapeutics
- Osocimab (BAY 1213790): Bayer Pharmaceuticals
- Milvexian: Bristol-Myers Squibb and Janssen Pharmaceuticals
- Isoquercetin: Quercis Pharmaceuticals
- ONO-7684: Ono Pharmaceutical
- VE-1902 is Verseon Corporation
- IONIS-FXI-LRx: Bayer Pharmaceuticals/Ionis Pharma
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Venous Thromboembolism Current Treatment Patterns
4. Venous Thromboembolism - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Venous Thromboembolism Late-Stage Products (Phase-III)
7. Venous Thromboembolism Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Venous Thromboembolism Discontinued Products
13. Venous Thromboembolism Product Profiles
14. Venous Thromboembolism Key Companies
15. Venous Thromboembolism Key Products
16. Dormant and Discontinued Products
17. Venous Thromboembolism Unmet Needs
18. Venous Thromboembolism Future Perspectives
19. Venous Thromboembolism Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/venous-thromboembolism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Venous Thromboembolism Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Quercis Pharma, Anthos Therapeutics, Bayer, BMS, Janssen, O here
News-ID: 2928325 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Venous
States Venous Stents Market Projected to Witness Expansion with Rising Incidence …
States Venous Stents Market Overview
The States Venous Stents Market is expected to grow from USD 1.3 billion in 2025 to USD 2.4 billion by 2032, registering a CAGR of 8.9%.
Coherent Market Insights is pleased to release its latest States Venous Stents Market research report, offering an in-depth analysis of the U.S. States Venous Stents Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels,…
Venous Stent Market Grows with Rising Cases of Chronic Venous Disorders | Boston …
Venous Stent Market Overview
The venous stent market is anticipated to grow from USD 0.6 billion in 2025 to USD 1.3 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period.
Coherent Market Insights is proud to announce the release of its latest market research report, providing a comprehensive analysis of the Venous Stent Market Landscape from 2025 to 2032. This report delivers precise forecasts across global, regional, and country…
Major Force in the Venous Thromboembolism Market 2025: Impact Of Healthcare Infr …
How Will the Venous Thromboembolism Market Grow, and What Is the Projected Market Size?
Over the past few years, the venous thromboembolism market has experienced a steady increase in its size. It's projected to expand from $2.44 billion in 2024 to $2.55 billion in 2025, rising at a compound annual growth rate (CAGR) of 4.4%. The growth during the historic period can be credited to an increasing elderly population, progress in…
Venous Catheter Market Size 2024 to 2031.
Market Overview and Report Coverage
A venous catheter is a small, flexible tube inserted into a vein for medical purposes such as accessing the bloodstream for medications, fluids, or blood sampling. The venous catheter market is expected to witness significant growth in the coming years, with a projected CAGR of 6.30% during the forecasted period.
The current outlook for the venous catheter market is positive, driven by factors such as…
Venous Skin Ulcer Treatment Market : Lucrative Opportunities
Venous Skin Ulcer Treatment Market: Introduction
According to the report, the global venous skin ulcer treatment market was valued at US$ 2.6 Bn in 2019. It is expected to expand at a CAGR of ~5% during the forecast period from 2020 to 2030. Various advanced technologies and treatment options are presently available for venous skin ulcer. The treatment for skin ulcer include different therapies such as compression therapy, advanced wound dressings,…
Increasing Prevalence of Venous Thromboembolism to Augment Growth of the Venous …
Venous thromboembolism (VTE) is the formation of blood clots in the bloodstream. Two main types of venous thromboembolism are pulmonary embolism and deep vein thrombosis. The formation of blood clots in a deep vein is called deep vein thrombosis, while the deep vein thrombosis formed breaks the clot and travels to the lungs, known as pulmonary embolism.
Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/188
Pulmonary embolism occurs in almost one-third of patients…
